Technical analysis of Liminatus Pharma, Inc. Class A Common Stock (LIMN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Price Performance
| 1 month | -48.77% |
| 3 months | -44.13% |
| Year-to-date | -89.08% |
| 1 year | -95.81% |
52-Week Range
| 52-week High | $141.50 |
| 52-week Low | $3.29 |
| Avg Volume (90d) | 580K |
Technical Indicators
| SMA 50 | $5.14 |
| SMA 200 | $16.91 |
| 30-day Volatility (annualised) | 133.4% |
| Price vs SMA 50 | -35.2% |
| Price vs SMA 200 | -80.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $69.50 | |
| 2025-11 | $52.00 | -25.2% |
| 2025-12 | $30.50 | -41.3% |
| 2026-01 | $27.51 | -9.8% |
| 2026-02 | $12.65 | -54.0% |
| 2026-03 | $8.60 | -32.0% |
| 2026-04 | $10.21 | +18.7% |
| 2026-05 | $8.20 | -19.7% |
| 2026-06 | $5.52 | -32.7% |
| 2026-07 | $5.15 | -6.7% |
| 2026-08 | $3.86 | -25.0% |
| 2026-09 | $3.33 | -13.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $3.33 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.08 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 4.80 |
| Current Ratio | 1.12 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -147.31 |